Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases
JournalJournal of Hepatology
MetadataShow full item record
AbstractBackground & Aims: Liver transplant (LT) recipients or other immunocompromised patients were not included in the registration trials of vaccine studies against SARS-CoV-2. Although clinical efficacy of COVID vaccines in immunocompromised patients was unknown, many societies had recommended vaccination of this highly vulnerable patient population. Methods: In this prospective study, we determined antibody (Ab) response to spike protein, 4 weeks after the 2nd dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine, in LT recipients and those with chronic liver diseases (CLD) with and without cirrhosis. Results: Of the 233 patients enrolled so far, 62 had LT, 79 had cirrhosis (10 decompensated) and 92 had CLD without cirrhosis. Ab titers were defined as undetectable (<0.40 U/mL), suboptimal (0.40 - 250 U/mL) and adequate (>250 U/mL). Of the 62 patients who had LT, Ab levels were undetectable in 11 patients and suboptimal (median titer 17.6, range 0.47 - 212 U/mL) in 27 patients. Among 79 patients with cirrhosis, 3 had undetectable Ab and 15 had suboptimal (median titer 41.3, range 0.49 - 221 U/L) response. Of the 92 patients without cirrhosis, four had undetectable Ab and 19 had suboptimal (median titer 95.5, range 4.9 - 234 U/L) Ab response. Liver transplantation, use of 2 or more immunosuppression medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor immune response on multivariable analysis. No patient had any serious adverse events. Conclusions: Poor antibody response after SARS-CoV-2 vaccination was seen in 61% of LT recipients and 24% of those with CLD.
Rights/TermsCopyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16564
- Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
- Authors: Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, Katchman E, Levi S, Houri I, Lubezky N, Shibolet O, Katchman H
- Issue date: 2021 Aug
- Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines.
- Authors: Narasimhan M, Mahimainathan L, Clark AE, Usmani A, Cao J, Araj E, Torres F, Sarode R, Kaza V, Lacelle C, Muthukumar A
- Issue date: 2021 Jun 30
- Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.
- Authors: Alqahtani SA, Barry M, Memish Z, Hashim A, Alfares MA, Alghamdi SA, Al-Hamoudi WK, Al-Judaibi B, Alhazzani W, Al-Tawfiq JA, Abaalkhail F
- Issue date: 2021 Jul-Aug
- SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients.
- Authors: Ruether DF, Schaub GM, Duengelhoef PM, Haag F, Brehm TT, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, Fischer L, Addo MM, Lütgehetmann M, Lohse AW, Schulze Zur Wiesch J, Sterneck M
- Issue date: 2021 Sep 9
- EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
- Authors: Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D
- Issue date: 2021 Apr